Novo Nordisk CEO: Semaglutide could create serious obesity treatment market
Come summer, Novo Nordisk will know whether semaglutide can be used as obesity treatment, and CEO Lars Fruergaard Jørgensen says this approval has potential to change the market for obesity treatment.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has great expectations for the potential launch of its drug, semaglutide, to treat severe obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk's CFO expects US growth boost this year
For subscribers
